Refreshing results…
IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience
UploadTP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
Download from ashpublications.orgMissing publications? Search for publications with a matching author name.